THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. An acylguanidine with antiviral activity.

2. An antiviral compound of Forumula I



I

wherein $R_1$-$R_4$ are independently aromatic groups, heteroaromatic groups, alkylaromatic groups, alkylheteroaromatic groups, alkenylaromatic groups, alkenylheteroaromatic groups, cycloalkylaromatic groups, cycloalkylheteroaromatic groups, aryloxyalkyl groups, heteroaryloxyalkyl groups, said groups are mono or polycyclic, and are optionally substituted with one or more substitutents independently selected from hydrogen, hydroxy, nitro, halo, amino, substituted amino, alkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, $C_{3-6}$cycloalkyl, halo-substituted $C_{1-6}$alkyl, halo-substituted $C_{1-6}$alkyloxy, phenyl, $C_{1-6}$alkeneyl, $C_{3-6}$cycloalkeneyl, $C_{1-6}$alkeneoxy, benzo, aryl, substituted aryl, PrS,  , or 

3. An antiviral compound of Formula I



I

or pharmaceutically acceptable salts thereof,

wherein,

$R_1$ =




, or ;

$R_2$ , $R_3$ and $R_4$ are independently hydrogen,





or



;

and wherein

X = hydrogen, hydroxy, nitro, halo, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, $C_{3-6}$cycloalkyl, halo-substituted $C_{1-6}$alkyl, halo-substituted $C_{1-6}$alkyloxy, phenyl, $C_{1-6}$alkeneyl, $C_{3-6}$cycloalkeneyl, $C_{1-6}$alkeneoxy, or benzo;

$R_a$, $R_b$, $R_c$, $R_d$, $R_e$, $R_f$, $R_h$, $R_k$, $R_L$, $R_m$, $R_n$, $R_o$, $R_p$ independently = hydrogen, amino, halo, $C_{1-5}$alkyl, $C_{1-5}$alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, mono or dialkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino,



or PrS;

$R_g$, $R_i$ independently = hydrogen, hydroxy, halo, or $C_{1-5}$ alkyl;

$R_j$ = hydrogen, amino, halo, $C_{1-5}$alkyl, $C_{1-5}$alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, alkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino, PrS,



;

4. A pharmaceutical composition comprising an antiviral compound according to any one of claims 1 to 3, and optionally one or more pharmaceutical acceptable carriers or derivatives.

5. The pharmaceutical composition according to claim 4, further comprising one or more known antiviral compounds or molecules.

6. A method for reducing, retarding or otherwise inhibiting growth and/or replication of a virus comprising contacting a cell infected with said virus or exposed to said virus with a compound according to any one of claims 1 to 3.

7. The method according to claim 6, wherein said virus is a Lentivirus.

8. The method according to claim 7, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

9. The method according to claim 8, wherein said compound is selected from the group consisting of :

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,

2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

10. The method according to claim 8, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.

11. The method according to any one of claims 8 to 10, wherein said HIV is HIV-1.

12. The method according to claim 6 wherein said virus is a Coronavirus.

13. The method according to claim 12, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

14. The method according to claim 13, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,

N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2=Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methyloinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

15. The method according to claim 13, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-napthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.

16. The method according to claim 12, wherein said Coronavirus is human Coronavirus 229E.

17. The method according to claim 16, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
5-(2'-bromophenyl)penta-2,4-dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-Pyrazinecarboxamide,

N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy –HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phynyl-2-Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-napthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

18. The method according to claim 16, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
3-(2-napthyl)acryloylguanidine,
2,4-dichlorocinnamolyguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-napthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-napthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-napthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N''-
Phenylguanidine.

19. The method according to claim 12, wherein said Coronavirus is human Coronavirus OC43.

20. The method according to claim 19, wherein said compound is selected from the group consisting of

3-methylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamolyguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

21. The method according to claim 12, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

22. The method according to claim 21, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine and
2-(2-napthyl)acetoylguanidine.

23. The method according to claim 12, wherein said Coronavirus is bovine Coronvirus (BCV).

24. The method according to claim 23, wherein said compound is selected from the group consisting of

(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.

25. The method according to claim 12, wherein said Coronavirus is any one of the known coronavirus isolates listed in Table 1.

26. The method according to claim 25, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

27. The method according to claim 6, wherein said virus is the Hepatitis C virus.

28. The method according to claim 27, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,

2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,

6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

29. The method according to claim 6, wherein said virus is Equine Arteritis virus.

30. The method according to claim 29, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1yl)cinnamoylguanidine.

31. A method according to any one of claims 6 to 30, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

32. A method for preventing the infection of a cell exposed to a virus comprising contacting said cell with a compound according to any one of claims 1 to 3.

33. The method according to claim 32, wherein said virus is a Lentivirus.

34. The method according to claim 33, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

35. The method according to claim 34, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N"-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-

pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

36. The method according to claim 34, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.

37. The method according to any one of claims 34 to 36, wherein said HIV is HIV-1.

38. The method according to claim 32 wherein said virus is a Coronavirus.

39. The method according to claim 38, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

40. The method according to claim 39, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,

(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,

2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

41. The method according to claim 39, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-napthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.

42. The method according to claim 38, wherein said Coronavirus is human Coronavirus 229E

43. The method according to claim 42, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,

3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,

3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrazinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy –HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phynyl-2-
Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,

N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-napthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

44. The method according to claim 42, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
3-(2-napthyl)acryloylguanidine,
2,4-dichlorocinnamolyguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,

2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-napthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-napthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-napthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N''-Phenylguanidine.

45. The method according to claim 38, wherein said Coronavirus is human Coronavirus OC43.

46. The method according to claim 45, wherein said compound is selected from the group consisting of

3-methylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,

2,4-dichlorocinnamolyguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

47. The method according to claim 38, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

48. The method according to claim 47, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine and
2-(2-napthyl)acetoylguanidine.

49. The method according to claim 38, wherein said Coronavirus is bovine Coronvirus (BCV).

50. The method according to claim 49, wherein said compound is selected from the group consisting of

(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and

4-phenylbenzoylguanidine.

51. The method according to claim 38, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

52. The method according to claim 51, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

53. The method according to claim 32, wherein said virus is the Hepatitis C virus.

54. The method according to claim 53, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,

3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,

[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

55. The method according to claim 32, wherein said virus is the Equine Arteritis virus.

---

56. The method according to claim 55, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1yl)cinnamoylguanidine.

57. The method according to any one of claims 32 to 56, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

58. A method for the therapeutic or prophylactic treatment of a subject infected with or exposed to a virus, comprising the administration of a compound according to any one of claims 1 to 3 to a subject in need of said treatment.

59. The method according to claim 58, wherein said virus is a Lentivirus.

60. The method according to claim 59, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

61. The method according to claim 60, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,

5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,

N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

62. The methods according to claim 60, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.

63. The method according to any one of claims 60 to 62, wherein said HIV is HIV-1.

64. The method according to claim 58 wherein said virus is a Coronavirus.

65. The method according to claim 64, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

66. The method according to claim 65, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,

cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,

2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

67. The method according to claim 65, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-napthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.

68. The method according to claim 64, wherein said Coronavirus is human Coronavirus 229E.

69. The method according to claim 68, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,

(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,

N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrazinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy –HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phynyl-2-
Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-napthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

70. The method according to claim 68, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,

5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
3-(2-napthyl)acryloylguanidine,
2,4-dichlorocinnamolyguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-napthoylguanidine,

6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-napthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-napthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N"-
Phenylguanidine.

71. The method according to claim 64, wherein said Coronavirus is human Coronavirus OC43.

72. The method according to claim 71, wherein said compound is selected from the group consisting of

3-methylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamolyguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

73. The method according to claim 64, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

74. The method according to claim 73, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,
Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine and
2-(2-napthyl)acetoylguanidine.

75. The method according to claim 64, wherein said Coronavirus is bovine Coronvirus (BCV).

76. The method according to claim 75, wherein said compound is selected from the group consisting of

(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-napthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.

77. The method according to claim 64, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

78. The method according to claim 77, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

79. The method according to claim 58, wherein said virus is the Hepatitis C virus.

80. The method according to claim 79, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,

4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

81. The method according to claim 58, wherein said virus is the Equine Arteritis virus.

82. The method according to claim 81, wherein said compound is selected from the group consisting of

5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-napthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1yl)cinnamoylguanidine.

83. The method according to any one of claims 58 to 82, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

84. A method of down regulating a membrane ion channel functional activity in a cell infected with a virus, comprising contacting said cell with a compound according to any one of claims 1 to 3.

85. The method according to claim 84, wherein said virus is a Lentivirus.

86. The method according to claim 85, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

87. The method according to claim 86, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

88. The method according to claim 87, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,

2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,

2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N"-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

89. The method according to any one of claims 86 to 88, wherein said HIV is HIV-1.

90. The method according to claim 84, wherein said virus is a Coronavirus.

91. The method according to claim 90, wherein said membrane ion channel is the Coronavirus E protein.

92. The method according to claim 91, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

93. The method according to claim 92, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,

2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

94. The method according to claim 91, wherein said Coronavirus is human Coronavirus 229E.

95. The method according to claim 94, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

96. The method according to claim 91, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

97. The method according to claim 96, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

98. The method according to claim 84, wherein said virus is the Hepatitis C virus.

99. The method according to claim 98, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

100. The method according to claim 99, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,

3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,

2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

101. The method according to any one of claims 84 to 100, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

102. A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell, said method comprising contacting said infected cell with a compound according to any one of claims 1 to 3, wherein said compound down regulates functional activity of a membrane ion channel derived from said virus and expressed in said infected cell.

103. The method according to claim 102, wherein said virus is a Lentivirus.

104. The method according to claim 103, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

105. The method according to claim 104, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

106. The method according to claim 105, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,

Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,

4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

107. The method according to any one of claims 104 to 106, wherein said HIV is HIV-1.

5

108. The method according to claim 102, wherein said virus is a Coronavirus.

109. The method according to claim 108, wherein said membrane ion channel is the Coronavirus E protein.

110. The method according to claim 109, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

111. The method according to claim 110, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,

2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

112. The method according to claim 109, wherein said Coronavirus is human Coronavirus 229E.

113. The method according to claim 112, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

114. The method according to claim 109, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

115. The method according to claim 114, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

116. The method according to claim 102, wherein said virus is the Hepatitis C virus.

117. The method according to claim 116, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

118. The method according to claim 117, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,

5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,

(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

119. The method according to any one of claims 102 to 118, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

120. A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell in a mammal, said method comprising administering to said mammal a compound according to any one of claims 1 to 3, wherein said compound down regulates functional activity of a membrane ion channel expressed in said infected cell.

121. The method according to claim 120, wherein said virus is a Lentivirus.

122. The method according to claim 121, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

123. The method according to claim 122, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,

2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,

(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy –HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

124. The method according to any one of claims 120 to 123, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

125. The method according to any one of claims 122 to 124, wherein said HIV is HIV-1.

126. The method according to claim 120, wherein said virus is a Coronavirus.

127. The method according to claim 126, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

128. The method according to claim 127, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

129. The method according to any one of claim 126 or 128, wherein said membrane ion channel is the Coronavirus E protein.

5

130. The method according to claim 126, wherein said Coronavirus is human Coronavirus 229E.

131. The method according to claim 130, wherein said compound is selected from the group consisting of

132. The method according to claim 131, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,

4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

133. The method according to any one of claims 130 or 132, wherein said membrane ion channel is the Coronavirus E protein.

134. The method according to claim 126, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

135. The method according to claim 134, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

136. The method according to claim 134 or claim 135, wherein said membrane ion channel is the Coronavirus E protein.

137. The method according to claim 120, wherein said virus is the Hepatitis C virus.

138. The method according to claim 137, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,

3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,

3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

139. The method according to claim 138, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

140. The method according to any one of claims 120 to 133, wherein said mammal is a primate.

---

141. The method according to any one of claims 137 to 139, wherein said mammal is a primate.

142. The method according to claim 140 or claim 141, wherein said primate is human.

143. The method according to any one of claims 120 to 142, wherein said compound is provided as a pharmaceutical composition according to claim 4 or claim 5.

144. A method for the therapeutic or prophylactic treatment of a subject infected with or exposed to a virus comprising administering to said subject a compound according to any one of claims 1 to 3, wherein said compound down-regulates functional activity of a membrane ion channel derived from said virus.

145. The method according to claim 144, wherein said virus is a Lentivirus.

146. The method according to claim 145, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

147. The method according to claim 146, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

148. The method according to claim 147, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-napthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,

2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-(1-napthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-(2-napthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N"-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,

1-napthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy --HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-napthoylguanidine.

149. The method according to any one of claims 146 to 148, wherein said HIV is HIV-1.

150. The method according to claim 144, wherein said virus is a Coronavirus.

151. The method according to claim 150, wherein said membrane ion channel is the Coronavirus E protein.

152. The method according to claim 151, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).

153. The method according to claim 152, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenzamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,

3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-napthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-napthyl)acetoylguanidine,
Cinnamoylguanidine,

(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
6-bromo-2-napthoylguanidine,
1-bromo-2-napthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-napthoyl)-N'-phenylguanidine.

---

154. The method according to claim 151, wherein said Coronavirus is human Coronavirus 229E.

5

155. The method according to claim 154, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-napthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,

4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-napthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-napthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-napthoylguanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,

(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-napthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

156. The method according to claim 151, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.

157. The method according to claim 156, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,

158. The method according to claim 144, wherein said virus is the Hepatitis C virus.

159. The method according to claim 158, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.

160. The method according to claim 159, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,

(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-napthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-napthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N''-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-napthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenzamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-napthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,

2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1yl)cinnamoylguanidine,
2-napthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-napthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

161. The method according to any one of claims 144 to 155, wherein said mammal is a primate.

162. The method according to any one of claims 158 to 160, wherein said mammal is a primate.

163. The method according to claim 161 or claim 162, wherein said primate is human.

164. An antiviral compound selected from the group consisting of
N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N'-phenyl-guanidine,
N-Benzyl-N'-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine,
3'4 DichloroBenzamil,

2'4 DichloroBenzamil,
5-(N-methyl-N-guanidinocarbonyl-methyl)amiloride,
5-(N-Methyl-N-isobutyl)amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(N,N-hexamethylene)amiloride,
5-(N,N-Diethyl)amiloride hydrochloride,
6-Iodoamiloride,
Bodipy-FL amiloride,
3-hydroxy-5-hexamethyleneimino-amiloride,
5-(4-fluorophenyl)amiloride,
5-tert-butylamino-amiloride,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
3-methoxy-5-(N,N-Hexamethylene)-amiloride,
3-methoxy-amiloride,
hexamethyleneimino-6-phenyl-2-pyrazinecarboximide,
N-amidino-3,5-diamino-6-phenyl-2-pyrazinecarboxamide,
1-napthoylguanidine,
2-napthoylguanidine,
N-(2-napthoyl)-N'-phenylguanidine,
N,N'-bis(2-napthoyl)guanidine,
N,N'-bis(1-napthoyl)guanidine,
N,N'-bis(2-napthoyl)-N''-phenylguanidine,
6-methoxy-2-naphthoylguanidine,
3-quinolinoylguanidine,
cinnamoylguanidine,
4-phenylbenzoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
(3-phenylpropanoyl)guanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,

trans-3-furanacryoylguanidine,
N-(6-Hydroxy-2-napthoyl)-N'-phenylguanidine,
(4-Phenoxybenzoyl)guanidine,
N,N'-Bis(amidino)napthalene-2,6-dicarboxamide,
N''-Cinnamoyl-N,N'-diphenylguanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
benzyoylguanidine,
(4-Chlorophenoxy-acetyl]guanidine,
N-benzoyl-N'-cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
(4-Chlorocinnamoyl)guanidine,
(4-Bromocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
(4-Hydroxycinnamoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
or pharmaceutically acceptable salts thereof.

165. A pharmaceutical composition comprising a compound according to claim 164, and optionally one or more pharmaceutical acceptable carriers or derivatives.

166. The pharmaceutical composition according to claim 165, further comprising one or more known antiviral compounds.

167. The method according to any one of claims 6 - 8,12 ,13, 16, 19, 21, 23, 25, 27, 29, 31, 32 to 34, 37 to 39, 42, 45, 47, 49, 51, 53, 55, 57, 58 to 60, 63 to 65, 68, 71, 73, 75, 77, 79, 81, 83 to 87, 89 to 92, 94 to 96, 98, 99, 101, 102, 103 to 105, 107 to 110, 112 to 114, 116, 117, 119, 120-122, 124-127, 129-131, 133-134, 136, 137, 139-147, 149-152, 154, 156, 158, or 159, wherein said compound is selected from the antiviral compounds according to claim 164.

168. The method according to any one of claims 6, 31,58,84,102 or 144, wherein said virus is Dengue virus and said compound is selected from the group consisting of cinnamoylguanidine, (2-chlorocinnamoyl)guanidine or trans-3-(1-napthyl)acryloylguanidine.